Hims & Hers stock rises 14% as FDA schedules peptide compounding review FDA takes first step in possible reversal of ban on some peptides The Washington Post Compounding warning letters to 503A facilities between 2017 and 2021 ScienceDirect Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed